Maik Pruess, PhD
Senior Field Application Scientist
October 26 2021 | 5:15 PM CET, Online
Two Sides of the Same Coin – ImmunoID NeXTTM and NeXT LiquidTM Biopsy: Comprehensive Platforms for Tumor Immunogenomics
- ImmunoID NeXT™ is an immunogenomics platform that provides comprehensive molecular data about each patient’s cancer and immune response. Via the interrogation and analysis of >20,000 genes in both DNA and RNA, the platform consolidates multiple biomarker assays into one; providing a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample. This is an end-to-end solution for immuno- and precision oncology biomarker discovery applications, simultaneously enabling the ultra-sensitive detection of somatic small and structural variants as well as the advanced analysis of tumor escape mechanisms, immune repertoire profiles, human leukocyte antigen (HLA) typing and loss of heterozygosity, neoantigen load, tumor mutational burden (TMB), microsatellite instability (MSI), oncovirus presence, gene and transcript expression signatures, and more.
- NeXT Liquid Biopsy™, our high-performance, exome-wide liquid biopsy assay (globally covers >20.000 genes), is designed to complement ImmunoID NeXT™. It exploits the inherent biology associated with cellular turnover in the tumor by capturing circulating cell-free DNA (cfDNA) molecules shed into the blood. This DNA is potentially representative of multiple regions of the primary tumor and/or distant metastases, thus complementing results from ImmunoID NeXT by enabling the exome-wide monitoring of both clonal and subclonal variants so that investigators have an extensive view of how the cancer evolves in response to therapy. As a first-of-its-kind, high-performance, exome-wide assay, NeXT Liquid Biopsy provides oncology translational and clinical researchers the ability to explore critical areas of tumor biology often not accessible in targeted gene panels.